Apotex Biotechnology Holdings Inc., Cangene deal

The companies signed a definitive agreement under which Apotex will acquire 85 percent of CNJ (Toronto), and CNJ will purchase 85 percent of Apotex's Rh Pharmaceuticals Inc. subsidiary (see BioCentury July 31).

Rh Pharmaceuticals is the developer of WinRho SD, for which licensee Univax Biologics Inc. (UNVX, Rockville, Md.) recently received FDA approval to treat idiopathic thrombocytopenic purpura and prevent Rh isoimmunization. ...